Author name: Inhibitec

We are thrilled to announce the publication of our study, “Humanized anti-BAMBI monoclonal antibody as a novel therapeutic strategy for psoriatic arthritis”, in Journal of Translational Medicine! This achievement marks an important milestone for Inhibitec and represents a significant step forward in the development of our humanized anti-BAMBI monoclonal antibody (hB101.37). Our findings demonstrate its […]

Inhibitec has received funding ((€3,533.45) through the Planes de Promoción Comercial program (NM25-PC-109), supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN). This grant allowed us to cover 50% of the funding for three international activities, which are part of its strategy to increase international visibility, open new markets, and expand its network of

Inhibitec Antibodies has been selected for the ‘Programa Personal Técnico I+D’, supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN), enabling us to expand our scientific team with the addition of a new R&D technician (RH25-XX-011). The funding awarded amounts to €17,177.16, representing a funding intensity of 59.15%, with an implementation period from 1

Inhibitec Antibodies has been one of the startups selected in the ‘Programa Personal Tecnico I+D’ supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN) to expand its scientific team with the addition of an R&D technician (RH23-XX-025). We greatly appreciate the support of SODERCAN for Inhibitec since the beginning of our project. https://boc.cantabria.es/boces/verAnuncioAction.do?idAnuBlob=386579

Towards a new therapy in psoriasis and psoriatic arthritis Inhibitec Anticuerpos S.L. has been selected as a recipient of the grant CPP2022-009666, supporting the development of the public–private collaborative project “Towards a new therapy in psoriasis and psoriatic arthritis”, within the framework of the Plan Estatal de Investigación Científica, Técnica y de Innovación (PEICTI) 2021–2023.

Towards a novel disruptive therapy in autoimmune disease We are thrilled to announce that Inhibitec has been selected as a recipient of the NEOTEC 2021 grant provided by CDTI (Center for Industrial Technological Development) with the support of the Ministerio de Ciencia e Innovación. This prestigious grant is designed to impulse new entrepreneurial projects that